デフォルト表紙
市場調査レポート
商品コード
1463904

経鼻ドラッグデリバリー市場-世界の産業規模、シェア、動向、機会、予測、薬物タイプ別、剤形別、治療用途別、エンドユーザー別、地域別、競合別、2019年~2029年

Nasal Drug Delivery Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Dosage Form, By Therapeutic Application, By End User, By Region and Competition, 2019-2029F

出版日: | 発行: TechSci Research | ページ情報: 英文 180 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.74円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

経鼻ドラッグデリバリー市場-世界の産業規模、シェア、動向、機会、予測、薬物タイプ別、剤形別、治療用途別、エンドユーザー別、地域別、競合別、2019年~2029年
出版日: 2024年04月15日
発行: TechSci Research
ページ情報: 英文 180 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

経鼻ドラッグデリバリーの世界市場は、2023年に586億7,000万米ドルと評価され、2029年までの予測期間のCAGRは7.44%で堅調な成長が予測されています。

経鼻ドラッグデリバリーの世界市場は、呼吸器疾患の有病率の増加、ドラッグデリバリー技術の進歩、非侵襲的な治療オプションに対する需要の高まりなどを背景に、近年大幅な成長を遂げています。経鼻ドラッグデリバリーは、迅速な作用発現、患者のコンプライアンス向上、他の投与経路と比較した全身的副作用の軽減など、数多くの利点を提供し、患者とヘルスケアプロバイダーの双方にとって魅力的な選択肢となっています。世界の経鼻ドラッグデリバリー市場の主な促進要因は、喘息、慢性閉塞性肺疾患(COPD)、鼻炎、鼻づまりなどの呼吸器疾患の発生率の上昇です。これらの疾患は世界中で数百万人に影響を及ぼしており、効果的な治療オプションに対する需要を牽引しています。経鼻ドラッグデリバリーは、患部に直接薬剤を送達することで、症状を緩和し、患者の全体的な生活の質を向上させる。ドラッグデリバリー技術の進歩も、市場の成長を促進する上で重要な役割を果たしています。点鼻薬、点滴、粉末、ゲル、軟膏などの技術革新により、コルチコステロイド、抗ヒスタミン薬、抗生物質、鎮痛薬など、鼻から投与できる薬剤の範囲が広がっています。精度、投与量制御、患者の利便性を改善した新しいデリバリー・デバイスの開発が、経鼻ドラッグ・デリバリー・システムの採用をさらに後押ししています。薬剤の自己投与傾向の高まりと在宅ヘルスケア重視の高まりが、世界の経鼻ドラッグデリバリー市場の拡大に寄与しています。在宅医療環境は、従来の病院や診療所ベースの治療に代わる便利で費用対効果の高い選択肢を提供し、患者が自宅で安全かつ効果的に使用できる経鼻薬物送達デバイスや製剤の需要を促進しています。

主な市場促進要因

呼吸器疾患の有病率の増加

ドラッグデリバリー技術の進歩

非侵襲的治療オプションへの需要の高まり

主な市場課題

鼻の刺激と不快感

薬物吸収のばらつき

主な市場動向

適応の拡大

患者中心のソリューションへの注力

セグメント別洞察

薬物タイプ別洞察

剤形別洞察

地域別洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の経鼻ドラッグデリバリー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 薬物タイプ別(抗ヒスタミン薬、副腎皮質ステロイド薬、麻酔薬、抗生物質、鎮痛薬、その他)
    • 剤形別(スプレー、ドロップ、パウダー、ジェル軟膏)
    • 治療用途別(喘息、慢性閉塞性肺疾患(COPD)、鼻炎、嚢胞性線維症、鼻づまり)、
    • エンドユーザー別(在宅ケア、病院、クリニック)
    • 地域別
    • 企業別(2023年)
  • 市場マップ
    • 薬物タイプ別
    • 剤形別
    • 治療用途別
    • エンドユーザー別
    • 地域別

第6章 アジア太平洋地域の経鼻ドラッグデリバリー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 薬物タイプ別
    • 投与形態別
    • 治療用途別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • オーストラリア
    • 日本
    • 韓国

第7章 欧州の経鼻ドラッグデリバリー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 薬物タイプ別
    • 投与形態別
    • 治療用途別
    • エンドユーザー別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • 英国

第8章 北米の経鼻ドラッグデリバリー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 薬物タイプ別
    • 投与形態別
    • 治療用途別
    • エンドユーザー別
    • 国別
  • 北米国別分析
    • 米国
    • メキシコ
    • カナダ

第9章 南米の経鼻ドラッグデリバリー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 薬物タイプ別
    • 投与形態別
    • 治療用途別
    • エンドユーザー別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの経鼻ドラッグデリバリー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 薬物タイプ別
    • 投与形態別
    • 治療用途別
    • エンドユーザー別
    • 国別
  • MEA:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • エジプト

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品発表
  • 合併・買収

第13章 経鼻ドラッグデリバリーの世界市場SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • GlaxoSmithKline Plc
  • Pfizer, Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Becton Dickson Company
  • Cadila Pharmaceuticals Ltd.
  • M Company
  • Johnson Johnson
  • Sanofi S.A.
  • Merck Co., Inc.

第16章 戦略的提言

第17章 免責事項

目次
Product Code: 5174

Global Nasal Drug Delivery Market was valued at USD 58.67 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 7.44% through 2029. The Global Nasal Drug Delivery Market has witnessed substantial growth in recent years, driven by the increasing prevalence of respiratory disorders, advancements in drug delivery technology, and rising demand for non-invasive treatment options. Nasal drug delivery offers numerous advantages, including rapid onset of action, improved patient compliance, and reduced systemic side effects compared to other routes of administration, making it an attractive option for both patients and healthcare providers. The key drivers of the global nasal drug delivery market is the rising incidence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), rhinitis, and nasal congestion. These conditions affect millions of individuals worldwide, driving the demand for effective treatment options. Nasal drug delivery provides targeted delivery of medications directly to the affected area, offering symptomatic relief and improving overall quality of life for patients. Advancements in drug delivery technology have also played a significant role in fueling market growth. Innovations such as nasal sprays, drops, powders, gels, and ointments have expanded the range of drugs that can be delivered nasally, including corticosteroids, antihistamines, antibiotics, and pain relief medications. The development of novel delivery devices with improved precision, dosage control, and patient convenience has further boosted the adoption of nasal drug delivery systems. The growing trend towards self-administration of medications and the increasing emphasis on home healthcare have contributed to the expansion of the global nasal drug delivery market. Home care settings provide a convenient and cost-effective alternative to traditional hospital and clinic-based treatments, driving the demand for nasal drug delivery devices and formulations that can be used safely and effectively by patients at home.

Key Market Drivers

Increasing Prevalence of Respiratory Disorders

The increasing prevalence of respiratory disorders is a significant driver of the Global Nasal Drug Delivery Market. Respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), rhinitis, and nasal congestion affect millions of individuals worldwide, driving the demand for effective treatment options. Nasal drug delivery plays a crucial role in providing targeted and efficient treatment for these respiratory disorders. Nasal formulations deliver medications directly to the affected areas of the respiratory tract, including the nasal passages, sinuses, and lungs, offering rapid onset of action and symptom relief. For conditions like rhinitis and nasal congestion, nasal sprays and drops are commonly used to deliver corticosteroids, antihistamines, and decongestants directly to the nasal mucosa, reducing inflammation and congestion. Similarly, for asthma and COPD, nasal inhalers deliver bronchodilators and corticosteroids to the lungs through the nasal passages, providing relief from symptoms such as wheezing and shortness of breath. The increasing burden of respiratory disorders, driven by factors such as air pollution, smoking, and aging populations, is expected to further fuel the demand for nasal drug delivery systems. The COVID-19 pandemic has highlighted the importance of respiratory health, leading to greater awareness and emphasis on effective treatment options for respiratory conditions. The increasing prevalence of respiratory disorders underscores the critical role of nasal drug delivery in providing targeted and efficient treatment, driving market growth for nasal drug delivery systems globally.

Advancements in Drug Delivery Technology

Advancements in drug delivery technology have significantly contributed to the growth and evolution of the Global Nasal Drug Delivery Market. These advancements encompass a wide range of innovations, including improved formulations, novel delivery devices, and enhanced drug stability, all of which have expanded the capabilities and applications of nasal drug delivery systems. Advancement is the development of optimized nasal formulations that enhance drug absorption, bioavailability, and duration of action. Formulation technologies such as nano emulsions, liposomes, and microspheres enable the encapsulation of drugs to improve solubility and stability, facilitating efficient drug delivery through the nasal mucosa. Novel delivery devices have been designed to enhance the precision, convenience, and user-friendliness of nasal drug delivery systems. These devices include metered-dose nasal sprays, dry powder inhalers, and nasal drug delivery devices equipped with electronic sensors for dose monitoring and administration feedback. These advancements improve patient compliance and ensure accurate dosing, leading to better therapeutic outcomes. Advancements in drug stability technologies have enabled the development of nasal formulations with improved shelf life and stability, allowing for long-term storage and distribution without compromising efficacy. Stabilization techniques such as freeze-drying, lyophilization, and spray drying enhance the stability of drugs in nasal formulations, ensuring consistent drug delivery and efficacy over time. Advancements in drug delivery technology have revolutionized the capabilities of nasal drug delivery systems, making them more effective, reliable, and versatile. These advancements drive innovation in the Global Nasal Drug Delivery Market, expanding the range of medications that can be delivered nasally and providing patients with more efficient and convenient treatment options for a wide range of medical conditions.

Growing Demand for Non-Invasive Treatment Options

The Global Nasal Drug Delivery Market is experiencing a surge in demand due to the growing preference for non-invasive treatment options among patients and healthcare providers alike. Non-invasive drug delivery methods offer several advantages over traditional routes of administration, such as oral or parenteral, including reduced systemic side effects, improved patient compliance, and enhanced therapeutic outcomes. Nasal drug delivery is particularly favored for its non-invasive nature and ability to deliver medications directly to the target site, bypassing the gastrointestinal tract and liver metabolism. This direct delivery route allows for rapid onset of action and higher drug bioavailability, making nasal drug delivery an attractive option for a wide range of medical conditions. Patients prefer non-invasive treatment options due to their convenience and reduced discomfort compared to invasive procedures. Nasal drug delivery methods such as sprays, drops, and inhalers are easy to use and can be self-administered by patients at home, eliminating the need for frequent clinic visits or hospitalizations. Healthcare providers recognize the benefits of non-invasive drug delivery in improving patient adherence to treatment regimens and enhancing overall treatment outcomes. Nasal drug delivery systems offer precise dosing and consistent drug delivery, ensuring optimal therapeutic effects while minimizing the risk of adverse reactions. The growing demand for non-invasive treatment options, coupled with advancements in nasal drug delivery technology, is driving the expansion of the Global Nasal Drug Delivery Market. As the preference for non-invasive therapies continues to rise, nasal drug delivery is poised to play a pivotal role in meeting the evolving healthcare needs of patients worldwide.

Key Market Challenges

Nasal Irritation and Discomfort

Nasal irritation and discomfort present significant challenges in the Global Nasal Drug Delivery Market, impacting patient compliance and treatment efficacy. Nasal drug delivery systems, including sprays, drops, and inhalers, rely on the nasal route to administer medications directly to the nasal mucosa. However, some patients may experience discomfort or irritation upon administration, leading to reluctance or discontinuation of treatment. The primary causes of nasal irritation is the presence of irritants or preservatives in nasal formulations. Ingredients such as benzalkonium chloride, used as a preservative in nasal sprays, can irritate the nasal mucosa and cause discomfort upon application. The pH and osmolarity of nasal formulations can affect nasal tolerability, with solutions that are too acidic or hypertonic causing irritation. Improper administration techniques, such as incorrect positioning of the nasal device or excessive force during spraying, can contribute to nasal discomfort. Patients may also experience irritation due to the mechanical action of the nasal device or the presence of foreign particles in the formulation. Nasal irritation and discomfort pose challenges for both patients and healthcare providers in the Global Nasal Drug Delivery Market. Patients may be hesitant to use nasal drug delivery systems if they experience discomfort, leading to poor treatment adherence and suboptimal therapeutic outcomes. Healthcare providers must carefully consider the tolerability and comfort of nasal formulations when prescribing medications, selecting formulations with minimal irritants and appropriate pH and osmolarity levels. Addressing nasal irritation and discomfort requires collaboration between pharmaceutical companies, healthcare providers, and regulatory agencies to develop formulations that are well-tolerated, comfortable to use, and efficacious, ultimately enhancing patient compliance and driving the growth of the Global Nasal Drug Delivery Market.

Variable Drug Absorption

Variable drug absorption presents a significant challenge in the Global Nasal Drug Delivery Market, impacting the efficacy and consistency of treatment outcomes. Nasal drug delivery systems are designed to deliver medications directly to the nasal mucosa, bypassing the gastrointestinal tract and liver metabolism, thereby offering rapid onset of action and high drug bioavailability. However, several factors can contribute to variability in drug absorption among individuals. The key factors influencing variable drug absorption is the anatomy and physiology of the nasal cavity. Variations in nasal anatomy, such as nasal septum deviation or nasal polyps, can affect the distribution and absorption of drugs within the nasal cavity, leading to inconsistent drug delivery. Differences in nasal mucociliary clearance rates and nasal blood flow can further contribute to variability in drug absorption among patients. Nasal pathology, such as chronic rhinitis or sinusitis, can impact the integrity of the nasal mucosa and alter drug absorption rates. Patients with nasal congestion or inflammation may experience reduced drug absorption, leading to suboptimal therapeutic outcomes. The individual patient characteristics, such as age, gender, and genetic factors, can influence drug absorption rates and nasal drug disposition. Variability in nasal drug absorption poses challenges for healthcare providers in optimizing treatment regimens and achieving consistent therapeutic effects. Addressing variable drug absorption requires advancements in nasal drug delivery technology and formulation design to improve drug distribution and absorption within the nasal cavity. The personalized medicine approaches, such as pharmacogenomics, may help identify patients who are at risk of variable drug absorption and tailor treatment regimens accordingly. Overall, mitigating variability in drug absorption is crucial for maximizing the effectiveness of nasal drug delivery systems and improving patient outcomes in the Global Nasal Drug Delivery Market.

Key Market Trends

Expansion of Indications

The expansion of indications is a significant trend shaping the Global Nasal Drug Delivery Market, driving the development and adoption of nasal drug delivery systems across a wide range of therapeutic areas. Traditionally used for respiratory disorders, nasal drug delivery is now expanding into various other medical fields, offering targeted and efficient treatment options for diverse patient populations.

One key area witnessing expansion is central nervous system (CNS) disorders, including migraine, epilepsy, and Parkinson's disease. Nasal drug delivery offers a non-invasive route to deliver medications directly to the brain, bypassing the blood-brain barrier and potentially improving drug efficacy and patient outcomes. For example, nasal formulations of migraine medications such as sumatriptan have been developed to provide rapid relief from migraine symptoms.

The hormonal therapies are another emerging area of interest for nasal drug delivery. Nasal formulations of hormones such as estradiol and testosterone offer advantages such as rapid absorption, improved bioavailability, and reduced systemic side effects compared to oral administration. These formulations are used for hormone replacement therapy, contraception, and management of hormonal disorders. Nasal drug delivery is being explored for vaccine administration, offering a needle-free alternative to traditional injectable vaccines. Nasal vaccines induce mucosal immunity and are well-suited for mass vaccination campaigns, particularly in pediatric and developing country settings. Nasal formulations of vaccines against influenza, COVID-19, and other infectious diseases are under development and have the potential to revolutionize vaccination strategies globally. The expansion of indications for nasal drug delivery systems is driving market growth and innovation, offering new opportunities to address unmet medical needs and improve patient care across various therapeutic areas.

Focus on Patient-centric Solutions

The Global Nasal Drug Delivery Market is witnessing a significant focus on patient-centric solutions, driven by the increasing emphasis on enhancing patient experience, adherence, and overall treatment outcomes. Manufacturers, healthcare providers, and regulatory agencies are prioritizing the development and adoption of nasal drug delivery systems that prioritize patient comfort, convenience, and usability. The key aspect of patient-centric solutions in the nasal drug delivery market is the development of user-friendly nasal devices. Manufacturers are designing nasal sprays, drops, and inhalers with ergonomic designs, intuitive operation, and easy-to-follow instructions to improve patient satisfaction and compliance. These devices are equipped with features such as dose counters, visual indicators, and audible cues to ensure accurate dosing and administration. There is a growing focus on developing nasal formulations that minimize discomfort and irritation for patients. Formulation technologies such as microemulsions, liposomes, and mucoadhesive polymers are being utilized to improve the tolerability and nasal comfort of medications delivered nasally. By reducing irritation and discomfort, these formulations enhance patient acceptance and adherence to treatment regimens. Patient education and support initiatives play a crucial role in promoting patient-centricity in the nasal drug delivery market. Healthcare providers are actively engaging patients through educational materials, counseling sessions, and digital platforms to empower them with information about their nasal medications, administration techniques, and potential side effects. By fostering patient understanding and involvement in their treatment, these initiatives promote adherence and improve treatment outcomes. The focus on patient-centric solutions in the Global Nasal Drug Delivery Market reflects a commitment to improving patient experience and outcomes. By prioritizing patient comfort, convenience, and education, stakeholders in the nasal drug delivery market aim to enhance treatment adherence, satisfaction, and ultimately, the quality of patient care.

Segmental Insights

Drug Type Insights

Based ondrug type,Corticosteroids segment dominated the Global Nasal Drug Delivery Market in 2023.This is due to the widespread use of corticosteroids for the treatment of various nasal conditions, including allergic rhinitis, nasal congestion, and sinusitis. Corticosteroids effectively reduce inflammation and swelling in the nasal passages, providing relief from symptoms associated with these conditions. Advancements in nasal drug delivery technologies have enhanced the efficacy and convenience of administering corticosteroids nasally, further driving their popularity and dominance in the global market for nasal drug delivery solutions.

Dosage Form Insights

Based on dosage form, Sprays segment dominated the Global Nasal Drug Delivery Market in 2023. This is due to due to their convenience, ease of use, and rapid onset of action. Nasal sprays offer precise dosing and uniform distribution of medication within the nasal cavity, ensuring optimal drug delivery. Advancements in spray technology have led to the development of fine mist sprays that enhance patient comfort and compliance. With their effectiveness in delivering various medications, including corticosteroids and antihistamines, nasal sprays continue to dominate the market for nasal drug delivery solutions globally.

Regional Insights

North America is dominating the Global Nasal Drug Delivery Market. This is due to North America boasts advanced healthcare infrastructure and a strong pharmaceutical industry, which fosters innovation and development in drug delivery technologies. The region is home to numerous pharmaceutical companies and research institutions that are at the forefront of nasal drug delivery research and development. These organizations have the resources, expertise, and capabilities to invest in cutting-edge technologies and bring novel nasal drug delivery products to market.

Key Market Players

GlaxoSmithKline Plc

Pfizer, Inc.

AstraZeneca PLC

Novartis AG

Becton Dickson Company

Cadila Pharmaceuticals Ltd.

3M Company

Johnson Johnson

Sanofi S.A.

Merck Co., Inc.

Report Scope:

In this report, the Global Nasal Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nasal Drug Delivery Market,By Drug Type:

  • Antihistamines
  • Corticosteroids
  • Anesthetics
  • Antibiotics
  • Pain Relief Drugs
  • Others

Nasal Drug Delivery Market,By Dosage Form:

  • Sprays
  • Drops
  • Powder
  • Gels Ointments

Nasal Drug Delivery Market,By Therapeutic Application:

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Rhinitis
  • Cystic Fibrosis
  • Nasal Congestion

Nasal Drug Delivery Market,By End User:

  • Home Care Settings
  • Hospitals
  • Clinics

Nasal Drug Delivery Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nasal Drug Delivery Market.

Available Customizations:

Global Nasal Drug Delivery Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validation
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.Global Nasal Drug Delivery Market Outlook

  • 5.1.Market Size Forecast
    • 5.1.1.By Value
  • 5.2.Market Share Forecast
    • 5.2.1.By Drug Type (Antihistamines, Corticosteroids, Anesthetics, Antibiotics, Pain Relief Drugs, Others)
    • 5.2.2.By Dosage Form (Sprays, Drops, Powder, Gels Ointments)
    • 5.2.3.By Therapeutic Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Rhinitis, Cystic Fibrosis, Nasal Congestion),
    • 5.2.4.By End User (Home Care Settings, Hospitals, Clinics)
    • 5.2.5.By Region
    • 5.2.6.By Company (2023)
  • 5.3.Market Map
    • 5.3.1.By Drug Type
    • 5.3.2.By Dosage Form
    • 5.3.3.By Therapeutic Application
    • 5.3.4.By End User
    • 5.3.5.By Region

6.Asia Pacific Nasal Drug Delivery Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Drug Type
    • 6.2.2.By Dosage Form
    • 6.2.3.By Therapeutic Application
    • 6.2.4.By End User
    • 6.2.5.By Country
  • 6.3.Asia Pacific: Country Analysis
    • 6.3.1.China Nasal Drug Delivery Market Outlook
      • 6.3.1.1.Market Size Forecast
        • 6.3.1.1.1.By Value
      • 6.3.1.2.Market Share Forecast
        • 6.3.1.2.1.By Drug Type
        • 6.3.1.2.2.By Dosage Form
        • 6.3.1.2.3.By Therapeutic Application
        • 6.3.1.2.4.By End User
    • 6.3.2.India Nasal Drug Delivery Market Outlook
      • 6.3.2.1.Market Size Forecast
        • 6.3.2.1.1.By Value
      • 6.3.2.2.Market Share Forecast
        • 6.3.2.2.1.By Drug Type
        • 6.3.2.2.2.By Dosage Form
        • 6.3.2.2.3.By Therapeutic Application
        • 6.3.2.2.4.By End User
    • 6.3.3.Australia Nasal Drug Delivery Market Outlook
      • 6.3.3.1.Market Size Forecast
        • 6.3.3.1.1.By Value
      • 6.3.3.2.Market Share Forecast
        • 6.3.3.2.1.By Drug Type
        • 6.3.3.2.2.By Dosage Form
        • 6.3.3.2.3.By Therapeutic Application
        • 6.3.3.2.4.By End User
    • 6.3.4.Japan Nasal Drug Delivery Market Outlook
      • 6.3.4.1.Market Size Forecast
        • 6.3.4.1.1.By Value
      • 6.3.4.2.Market Share Forecast
        • 6.3.4.2.1.By Drug Type
        • 6.3.4.2.2.By Dosage Form
        • 6.3.4.2.3.By Therapeutic Application
        • 6.3.4.2.4.By End User
    • 6.3.5.South Korea Nasal Drug Delivery Market Outlook
      • 6.3.5.1.Market Size Forecast
        • 6.3.5.1.1.By Value
      • 6.3.5.2.Market Share Forecast
        • 6.3.5.2.1.By Drug Type
        • 6.3.5.2.2.By Dosage Form
        • 6.3.5.2.3.By Therapeutic Application
        • 6.3.5.2.4.By End User

7.Europe Nasal Drug Delivery Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.By Drug Type
    • 7.2.2.By Dosage Form
    • 7.2.3.By Therapeutic Application
    • 7.2.4.By End User
    • 7.2.5.By Country
  • 7.3.Europe: Country Analysis
    • 7.3.1.France Nasal Drug Delivery Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.By Drug Type
        • 7.3.1.2.2.By Dosage Form
        • 7.3.1.2.3.By Therapeutic Application
        • 7.3.1.2.4.By End User
    • 7.3.2.Germany Nasal Drug Delivery Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.By Drug Type
        • 7.3.2.2.2.By Dosage Form
        • 7.3.2.2.3.By Therapeutic Application
        • 7.3.2.2.4.By End User
    • 7.3.3.Spain Nasal Drug Delivery Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecast
        • 7.3.3.2.1.By Drug Type
        • 7.3.3.2.2.By Dosage Form
        • 7.3.3.2.3.By Therapeutic Application
        • 7.3.3.2.4.By End User
    • 7.3.4.Italy Nasal Drug Delivery Market Outlook
      • 7.3.4.1.Market Size Forecast
        • 7.3.4.1.1.By Value
      • 7.3.4.2.Market Share Forecast
        • 7.3.4.2.1.By Drug Type
        • 7.3.4.2.2.By Dosage Form
        • 7.3.4.2.3.By Therapeutic Application
        • 7.3.4.2.4.By End User
    • 7.3.5.United Kingdom Nasal Drug Delivery Market Outlook
      • 7.3.5.1.Market Size Forecast
        • 7.3.5.1.1.By Value
      • 7.3.5.2.Market Share Forecast
        • 7.3.5.2.1.By Drug Type
        • 7.3.5.2.2.By Dosage Form
        • 7.3.5.2.3.By Therapeutic Application
        • 7.3.5.2.4.By End User

8.North America Nasal Drug Delivery Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Drug Type
    • 8.2.2.By Dosage Form
    • 8.2.3.By Therapeutic Application
    • 8.2.4.By End User
    • 8.2.5.By Country
  • 8.3.North America: Country Analysis
    • 8.3.1.United States Nasal Drug Delivery Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Drug Type
        • 8.3.1.2.2.By Dosage Form
        • 8.3.1.2.3.By Therapeutic Application
        • 8.3.1.2.4.By End User
    • 8.3.2.Mexico Nasal Drug Delivery Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Drug Type
        • 8.3.2.2.2.By Dosage Form
        • 8.3.2.2.3.By Therapeutic Application
        • 8.3.2.2.4.By End User
    • 8.3.3.Canada Nasal Drug Delivery Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Drug Type
        • 8.3.3.2.2.By Dosage Form
        • 8.3.3.2.3.By Therapeutic Application
        • 8.3.3.2.4.By End User

9.South America Nasal Drug Delivery Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Drug Type
    • 9.2.2.By Dosage Form
    • 9.2.3.By Therapeutic Application
    • 9.2.4.By End User
    • 9.2.5.By Country
  • 9.3.South America: Country Analysis
    • 9.3.1.Brazil Nasal Drug Delivery Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Drug Type
        • 9.3.1.2.2.By Dosage Form
        • 9.3.1.2.3.By Therapeutic Application
        • 9.3.1.2.4.By End User
    • 9.3.2.Argentina Nasal Drug Delivery Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Drug Type
        • 9.3.2.2.2.By Dosage Form
        • 9.3.2.2.3.By Therapeutic Application
        • 9.3.2.2.4.By End User
    • 9.3.3.Colombia Nasal Drug Delivery Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Drug Type
        • 9.3.3.2.2.By Dosage Form
        • 9.3.3.2.3.By Therapeutic Application
        • 9.3.3.2.4.By End User

10.Middle East and Africa Nasal Drug Delivery Market Outlook

  • 10.1.Market Size Forecast
    • 10.1.1.By Value
  • 10.2.Market Share Forecast
    • 10.2.1.By Drug Type
    • 10.2.2.By Dosage Form
    • 10.2.3.By Therapeutic Application
    • 10.2.4.By End User
    • 10.2.5.By Country
  • 10.3.MEA: Country Analysis
    • 10.3.1.South Africa Nasal Drug Delivery Market Outlook
      • 10.3.1.1.Market Size Forecast
        • 10.3.1.1.1.By Value
      • 10.3.1.2.Market Share Forecast
        • 10.3.1.2.1.By Drug Type
        • 10.3.1.2.2.By Dosage Form
        • 10.3.1.2.3.By Therapeutic Application
        • 10.3.1.2.4.By End User
    • 10.3.2.Saudi Arabia Nasal Drug Delivery Market Outlook
      • 10.3.2.1.Market Size Forecast
        • 10.3.2.1.1.By Value
      • 10.3.2.2.Market Share Forecast
        • 10.3.2.2.1.By Drug Type
        • 10.3.2.2.2.By Dosage Form
        • 10.3.2.2.3.By Therapeutic Application
        • 10.3.2.2.4.By End User
    • 10.3.3.UAE Nasal Drug Delivery Market Outlook
      • 10.3.3.1.Market Size Forecast
        • 10.3.3.1.1.By Value
      • 10.3.3.2.Market Share Forecast
        • 10.3.3.2.1.By Drug Type
        • 10.3.3.2.2.By Dosage Form
        • 10.3.3.2.3.By Therapeutic Application
        • 10.3.3.2.4.By End User
    • 10.3.4.Egypt Nasal Drug Delivery Market Outlook
      • 10.3.4.1.Market Size Forecast
        • 10.3.4.1.1.By Value
      • 10.3.4.2.Market Share Forecast
        • 10.3.4.2.1.By Drug Type
        • 10.3.4.2.2.By Dosage Form
        • 10.3.4.2.3.By Therapeutic Application
        • 10.3.4.2.4.By End User

11.Market Dynamics

  • 11.1.Drivers
  • 11.2.Challenges

12.Market Trends Developments

  • 12.1.Recent Developments
  • 12.2.Product Launches
  • 12.3.Mergers Acquisitions

13.Global Nasal Drug Delivery Market: SWOT Analysis

14.Porter's Five Forces Analysis

  • 14.1.Competition in the Industry
  • 14.2.Potential of New Entrants
  • 14.3.Power of Suppliers
  • 14.4.Power of Customers
  • 14.5.Threat of Substitute Product

15.Competitive Landscape

  • 15.1.GlaxoSmithKline Plc
    • 15.1.1.Business Overview
    • 15.1.2.Company Snapshot
    • 15.1.3.Products Services
    • 15.1.4.Financials (In case of listed)
    • 15.1.5.Recent Developments
    • 15.1.6.SWOT Analysis
  • 15.2.Pfizer, Inc.
  • 15.3.AstraZeneca PLC
  • 15.4.Novartis AG
  • 15.5.Becton Dickson Company
  • 15.6.Cadila Pharmaceuticals Ltd.
  • 15.7.3M Company
  • 15.8.Johnson Johnson
  • 15.9.Sanofi S.A.
  • 15.10.Merck Co., Inc.

16.Strategic Recommendations

17. About Us Disclaimer